Zacks Short Term Rating on Fresenius Medical Care Corporation (NYSE:FMS) - Insider Trading Report PDF Print

Fresenius Medical Care Corporation (NYSE:FMS) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks. The shares could manage an average rating of 2.67 from 9 analysts. As per the latest data, 1 analysts has given a sell rating on the shares of the company. 2 market experts have marked it as a strong buy. 6 analysts have rated the company at hold.

Fresenius Medical Care Corporation (NYSE:FMS): 5 analysts have set the short term price target of Fresenius Medical Care Corporation (NYSE:FMS) at $43.61. The standard deviation of short term price target has been estimated at $5.04, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 50 and $39 respectively. Many analysts have commented on the company rating. In a research note released to the investors, HSBC upgrades its rating on Fresenius Medical Care Corporation (NYSE:FMS). Investors must note that the brokerage house has a Neutral rating on the shares of the company. Previously, the company had a rating of Underweight. The rating by the firm was issued on February 27, 2015. Fresenius Medical Care Corporation (NYSE:FMS) rose 0.51% or 0.21 points on Monday and made its way into the gainers of the day. After trading began at $41.4 the stock was seen hitting $41.78 as a peak level and $41.37 as the lowest level. The stock ended up at $41.77. The daily volume was measured at 1,101,268 shares. The 52-week high of the share price is $44.34 and the 52-week low is $32.4. The company has a market cap of $26,081 million. Institutional Investors own 2% of Company shares. During last 3 month period, 1.24% of total institutional ownership has changed in the company shares. Fresenius Medical Care AG & Co KGaA is a Germany-based kidney dialysis company that operates in the fields of dialysis care and dialysis products for the treatment of end-stage renal disease (ESRD). Its dialysis business is vertically integrated and offers products and services for the entire dialysis value chain, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. The Company offers two types of dialysis treatment: Hemodialysis (HD), where the machine controls the blood from the patient through a special filter, the dialyzer, and Peritoneal Dialysis (PD), where the patients peritoneum is used as a dialyzing membrane. Its dialysis product portfolio includes chronic hemodialysis, home dialysis, renal pharmaceuticals, acute therapy, liver support, therapeutic apheresis, therapy support and water technology, among others. In addition, the Company sells dialysis products to other dialysis service providers.


Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.